■患有Ehlers-Danlos综合征(EDS)和高移动频谱障碍(HSD)的患者面临着大量的健康挑战,然而,它们在成本方面的影响尚不清楚。我们的研究目标是检查美国EDS和HSD的成本负担。我们的分析重点是那些有商业保险计划的人。
■我们查询了2021年的MarketScan®数据库,以获取包含针对EDS或超移动性的ICD-10诊断代码的索赔。EDS和HSD队列中患者的超额费用是通过将每个患者与数据库中没有EDS或HSD索赔的一名患者进行匹配并比较日历年的总费用来确定的。我们确定了患者是否有可能在日历年内影响成本的选定合并症的索赔。
■成人(年龄≥18岁)EDS患者的样本量为5,113,4,880例成人HSD患者,1,059名儿童(5-17岁)EDS患者,和2,427儿童HSD患者。成人EDS患者的平均超额费用为21,100美元,成人HSD患者$11,600,儿童EDS患者$17,000,以及儿童HSD患者$11,000。EDS和HSD队列,成人和儿童,任何合并症都有更高的医疗成本。在EDS队列中发现最大的差异与胃肠道合并症,成人的费用是成人的两倍多。
■我们发现MarketScan数据库中的患者,成人和儿童,考虑到年龄,患有EDS或HSD的患者比没有EDS或HSD的患者有更高的相关超额医疗费用,性别,地理位置,和合并症。这些人口中不成比例的医疗保健成本具有卫生政策和经济影响,包括快速诊断的需要,获得治疗,并加快研究以推进治疗。
UNASSIGNED: Patients with Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD) have significant health challenges that are well-documented, however their impact in terms of cost is not known. Our research objective was to examine the cost burden of EDS and HSD in the United States. We focused this analysis on those with commercial insurance plans.
UNASSIGNED: We queried the MarketScan® database for year 2021 for claims that contained an ICD-10 diagnosis code for EDS or hypermobility. Excess costs for patients in the EDS and HSD cohorts were determined by matching each patient to one patient in the database that did not have a claim for EDS or HSD and comparing total costs for the calendar year. We determined whether patients had claims for selected comorbid conditions likely to impact costs during the calendar year.
UNASSIGNED: Sample sizes were 5,113 for adult (age ≥ 18) patients with EDS, 4,880 for adult patients with HSD, 1,059 for child (age 5-17) patients with EDS, and 2,427 for child patients with HSD. The mean excess costs were $21,100 for adult EDS patients, $11,600 for adult HSD patients, $17,000 for child EDS patients, and $11,000 for child HSD patients. EDS and HSD cohorts, both adults and children, with any of the comorbidities had greater healthcare costs. The largest difference was found in the EDS cohort with gastrointestinal comorbid conditions, with more than double the costs for adults.
UNASSIGNED: We found that patients in the MarketScan database, adults and children, who had EDS or HSD had substantially higher associated excess healthcare costs than patients without EDS or HSD when considering age, sex, geographic location, and comorbidities. These disproportionate healthcare costs in this population have health policy and
economic implications, including the need for rapid diagnosis, access to treatment, and accelerated research to advance treatments.